Compare GNS & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNS | ATYR |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8M | 79.2M |
| IPO Year | 2022 | 2015 |
| Metric | GNS | ATYR |
|---|---|---|
| Price | $0.67 | $0.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 1.7M | ★ 2.2M |
| Earning Date | 09-23-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,749,894.00 | $190,000.00 |
| Revenue This Year | $82.78 | N/A |
| Revenue Next Year | $85.90 | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.21 | $0.64 |
| 52 Week High | $1.92 | $7.29 |
| Indicator | GNS | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 41.71 |
| Support Level | $0.62 | $0.70 |
| Resistance Level | $0.76 | $0.83 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 52.91 | 26.75 |
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education, which involves entrepreneur education, management consultancy, and business development tools; and Campus, consisting of resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America. The company derives maximum revenue from Europe/Middle East/Africa.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.